Tymlos Inclusion Stands Out As Express Scripts Reveals 2018 Formulary
Radius Health's pricing and reimbursement strategy has been successful, at least with Express Scripts, which included its bone-builder Tymlos on a 2018 formulary that excludes several brand-name drugs.
You may also be interested in...
Lilly will save $500m annually starting in 2018 after $1.2bn in layoff-related costs to reinvest in new products. Also, Cytori halves its headcount; VC OrbiMed closed a $551m Asia fund; and Insmed capitalizes on positive data.
Roivant will use the cash to fund other "Vants" that develop drugs or make the process more efficient. Also, Zealand launches its IPO, Apellis raises a $60m Series E and BioMarin tops recent offerings.
With Endo's announcement July 6 that it will conform with FDA's request to remove Opana ER from the market, the specialty firm's prospects seem tied even more tightly to its generics business.